文献速递胸部肿瘤

NRG-LU005 试验:局限期小细胞肺癌放化疗联合阿替利珠单抗的患者报告结局

Comprehensive Patient-Reported Outcomes from NRG Oncology/Alliance LU005: A Randomized Trial of Chemoradiation With or Without Atezolizumab in Limited-Stage SCLC.
PubMed 文献 · J Thorac Oncol · 2026-07-30

NRG-LU005 随机试验纳入 544 例局限期小细胞肺癌患者,比较放化疗联合或不联合阿替利珠单抗的患者报告结局。预设假设未证实:15 个月时 FACT-TOI 的临床意义下降在两组间无显著差异,免疫治疗组 21 个月时下降较少。每日两次放疗与所有时间点更好的 FACT-TOI 相关。

要点

  • 15 个月时 FACT-TOI 的临床意义下降在两组间无显著差异。
  • 免疫治疗组 21 个月时 FACT-TOI 临床意义下降较少。
  • 每日两次放疗与所有时间点更好的 FACT-TOI 相关。

核心结论

  • 放化疗联合阿替利珠单抗未显著改变 15 个月时 FACT-TOI 的临床意义下降。
  • EQ-5D-5L 和疲劳评分在两组间相似。
  • 每日两次放疗与更优的 PRO 轨迹相关,但非随机比较。

研究设计与样本

  • NRG-LU005 随机试验纳入 544 例局限期小细胞肺癌患者。
  • 患者随机接受标准放化疗(铂类+依托泊苷+胸部放疗,45 Gy 每日两次或 66 Gy 每日一次)联合或不联合阿替利珠单抗。
  • PRO 工具包括 FACT-TOI、EQ-5D-5L 和 PROMIS 疲劳,随访至 21 个月,EQ-5D-5L 至 24 个月。

主要发现

  • PRO 依从性基线超过 85%,至 21 个月稳定在 60%–68%。
  • 15 个月时 FACT-TOI 的临床意义下降在两组间无显著差异,免疫治疗组 21 个月时较少。
  • 每日两次放疗在所有时间点与更好的 FACT-TOI 相关。
  • 多变量分析中,每日两次放疗(放化疗结束时、15、21 个月)、体能状态(放化疗结束时)、顺铂(15 个月)和免疫治疗(21 个月)是 FACT-TOI 临床意义下降较低的显著预测因素。

临床怎么用

  • 联合阿替利珠单抗未显著改善 15 个月时 FACT-TOI 的临床意义下降。
  • 每日两次放疗可能与更好的患者报告结局轨迹相关,但需谨慎解读。

局限性

  • 放疗方案比较非随机设计。
  • PRO 依从性至 21 个月降至 60%–68%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: NRG-LU005 found no overall survival advantage with the addition of concurrent and adjuvant immunotherapy to chemoradiotherapy (CRT); however, it reported longer overall survival in an exploratory comparison of twice-daily versus once-daily radiation. This planned analysis assessed longitudinal patient-reported outcomes (PROs). The prespecified hypothesis was that clinically meaningful decline (CMD) in longer-term PROs at 15 months would be lower with immunotherapy, as measured by the Functional Assessment of Cancer Therapy: Trial Outcome Index (FACT-TOI). METHODS: Patients (N = 544) were randomized to receive standard CRT (platinum and etoposide + thoracic RT [45 Gy twice-daily or 66 Gy once-daily]) with or without atezolizumab starting at cycle 2 of chemotherapy. Stratification factors included radiation therapy (RT) schedule, chemotherapy type, sex, and performance status. PROs included validated instruments: FACT-TOI, EuroQol 5-Dimension 5-Level (EQ-5D-5L), and Patient-Reported Outcomes Measurement Information System Fatigue (at baseline, end of CRT, and at 3, 6, 15, and 21 mo). EQ-5D-5L scores were followed through 24 months. CMD and longitudinal trends were evaluated; multivariable logistic regression analysis adjusted for treatment arm, stratification factors, and baseline FACT-TOI. RESULTS: PRO compliance exceeded 85% at baseline and stabilized at 60% to 68% through 21 months. CMD in FACT-TOI was not meaningfully different between treatment arms at 15 months, though fewer patients in the immunotherapy arm had CMD at 21 months. EQ-5D-5L and Patient-Reported Outcomes Measurement Information System -fatigue scores were similar in both arms. Twice daily-RT was associated with better FACT-TOI than once-daily-RT at all time points. On multivariable logistic regression analysis, significant predictors of lower CMD for FACT-TOI (beyond baseline FACT-TOI) included twice-daily RT (at end-of-CRT, 15, and 21 mo), performance status (at end-of-CRT), cisplatin (at 15 mo), and immunotherapy (at 21 mo). CONCLUSIONS: The addition of atezolizumab to CRT was not associated with a significant change in CMD in FACT-TOI at 15 months, with similar EQ-5D-5L and fatigue scores. Although not randomized for RT schedule, this analysis suggests that twice-daily RT (versus once-daily RT) was associated with a consistently more favorable PRO trajectory. CLINICAL TRIAL INFORMATION: ClinicalTrials.gov Identifier: NCT03811002.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Movsas B, Hu C, Higgins KA, et al. Comprehensive Patient-Reported Outcomes from NRG Oncology/Alliance LU005: A Randomized Trial of Chemoradiation With or Without Atezolizumab in Limited-Stage SCLC. J Thorac Oncol. 2026. PMID: 42532339. doi:10.1016/j.jtho.2026.104117

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。